Text this: Safety, Tolerability, and Immunogenicity of a Recombinant Nonavalent Human Papillomavirus Vaccine (<i>Escherichia coli</i>) in Healthy Chinese Women Aged 18–45 Years: A Phase 1 Clinical Trial